ArticleHistopathology2020
Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
Article in Histopathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- World Health Organization classification of tumours of the breast 6th edition 2026.Histopathology · 2026Review
- A Rare Breast Tumor Presenting As Adenomyoepithelioma With Suspicious Imaging Features: A Case Report.Cureus · 2025Article
- Targeting malignant adenomyoepithelioma of the breast: clinical insights on multimodal therapy and disease-free survival.Discover oncology · 2025Article
- Molecular Basis of Breast Tumor Heterogeneity.Advances in experimental medicine and biology · 2025Review
- Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?OncoTargets and therapy · 2025Article
- Detection of RAS p.Q61R by Immunohistochemistry in Practice: A Clinicopathologic Study of 217 Thyroid Nodules with Molecular Correlates.Endocrine pathology · 2024Article
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- Article
- Confirmation of canine acanthomatous ameloblastoma using RAS Q61R immunohistochemical staining of formalin-fixed paraffin-embedded tissues.Frontiers in veterinary science · 2023Article
- Primary mucoepidermoid carcinoma of the breast arising in adenomyoepithelioma.BMJ case reports · 2022Article
- Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.Virchows Archiv : an international journal of pathology · 2022Review
- Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors.Frontiers in immunology · 2022Article
- NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility.Histopathology · 2021Article
- Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.Surgical pathology clinics · 2021Review
- Cross-reactivity of NRASQ61R antibody in a subset of Spitz nevi with 11p gain: a potential confounding factor in the era of pathway-based diagnostic approach.Human pathology · 2021Article
- Papillary neoplasms of the breast-reviewing the spectrum.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer.NPJ breast cancer · 2021Article
- Problematic breast tumors reassessed in light of novel molecular data.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 4 countries.
Funding
Abstract
aimsBreast adenomyoepitheliomas (AMEs) are uncommon tumours. Most oestrogen receptor (ER)-positive AMEs have mutations in phosphoinositide 3-kinase (PI3K) pathway genes, whereas ER-negative AMEs usually harbour concurrent mutations affecting the HRAS Q61 hotspot and PI3K pathway genes. Here, we sought to determine the sensitivity and specificity of RAS Q61R immunohistochemical (IHC) analysis for detection of HRAS Q61R mutations in AMEs. METHODS AND
resultsTwenty-six AMEs (14 ER-positive; 12 ER-negative) previously subjected to massively parallel sequencing (n = 21) or Sanger sequencing (n = 5) of the HRAS Q61 hotspot locus were included in this study. All AMEs were subjected to IHC analysis with a monoclonal (SP174) RAS Q61R-specific antibody, in addition to detailed histopathological analysis. Nine ER-negative AMEs harboured HRAS mutations, including Q61R (n = 7) and Q61K (n = 2) mutations. Five of seven (71%) AMEs with HRAS Q61R mutations were immunohistochemically positive, whereas none of the AMEs lacking HRAS Q61R mutations (n = 17) were immunoreactive. RAS Q61R immunoreactivity was restricted to the myoepithelium in 80% (4/5) of cases, whereas one case showed immunoreactivity in both the epithelial component and the myoepithelial component. RAS Q61R immunohistochemically positive AMEs were associated with infiltrative borders (P < 0.001), necrosis (P < 0.01) and mitotic index in the epithelial (P < 0.05) and myoepithelial (P < 0.01) components. RAS Q61R IHC assessment did not reveal Q61K mutations (0/2).
conclusionsIHC analysis of RAS Q61R shows high specificity (100%) and moderate sensitivity (71%) for detection of HRAS Q61R mutations in breast AMEs, and appears not to detect HRAS Q61K mutations. IHC analysis of RAS Q61R may constitute a useful technique in the diagnostic workup of ER-negative AMEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.